An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation,
please visit www.BMSStudyConnect.com

Inclusion Criteria:

- During dose escalation, subjects with advanced solid tumors that have progressed
following at least one standard regimen

- During cohort expansion, subjects with advanced cancer that either have received at
least one prior therapy or are treatment naive, depending on the specified tumor type

- Subjects must have measurable disease

- Subject must consent to provide previously collected tumor tissue and a tumor biopsy
during screening.

- At least 4 weeks since any previous treatment for cancer

- Must be able to swallow pills or capsules

- Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1

Exclusion Criteria:

- Active or chronic autoimmune diseases

- Uncontrolled or significant cardiovascular disease

- History of any chronic Hepatitis, active Hepatitis B or C, human immunodeficiency
virus (HIV), or acquired immune deficiency syndrome (AIDS)

- Chronic hepatitis: Positive test for Hepatitis B virus surface antigen or Hepatitis C
antibody (except for subjects with hepatocellular carcinoma)

- Active central nervous system (CNS) metastases and CNS metastases as the only sites of
disease

- Active infection

Other protocol defined inclusion/exclusion criteria could apply